T Lebret

Summary

Affiliation: Hopital Foch
Country: France

Publications

  1. ncbi Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction
    Thierry Lebret
    Urology Department, Hopital Foch, Suresnes 92151, France
    Eur Urol 41:608-13; discussion 613. 2002
  2. ncbi [Study of survival after cystectomy for bladder cancer. Report of 504 cases]
    T Lebret
    Service d Urologie, Hopital Foch, Suresnes, France
    Prog Urol 10:553-60. 2000
  3. ncbi After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?
    Thierry Lebret
    Department of Urology, Hopital Foch, 40 rue Worth, 92151 Suresnes, France
    Eur Urol 42:344-9; discussion 349. 2002
  4. ncbi [Treatment of bladder tumors]
    Thierry Lebret
    Service d urologie Hôpital Foch 92151 Suresnes
    Rev Prat 52:36-42. 2002
  5. ncbi A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction
    Y Neuzillet
    Department of Urology, Hopital Foch, Suresnes, France
    Andrology 1:223-8. 2013
  6. ncbi [Are therapeutics decisions homogeneous in multidisciplinary onco-urology staff meeting? Comparison of therapeutic options taken in four departments from Paris]
    F Audenet
    Service d Urologie, Universite Paris Descartes, Hopital Europeen Georges Pompidou, AP HP, 20, rue Leblanc, 75015 Paris, France
    Prog Urol 22:433-7. 2012
  7. ncbi Electrovaporization of the prostate with the Gyrus device
    H Botto
    Department of Urology H pital Foch, Suresnes, France
    J Endourol 15:313-6. 2001
  8. ncbi [Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]
    M O Timsit
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S365-75. 2008
  9. ncbi [Is the cytoreductive nephrectomy still necessary in case of metastases?]
    T Lebret
    Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
    Prog Urol 20:S33-7. 2010
  10. ncbi [The impact of partial nephrectomy on morbidity and on long-term oncological outcomes]
    Y Rouach
    Service d Urologie, Hopital Necker, Universite Rene Descartes, 69, rue Saint Martin, 75004 Paris, France
    Prog Urol 19:481-6. 2009

Collaborators

Detail Information

Publications67

  1. ncbi Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction
    Thierry Lebret
    Urology Department, Hopital Foch, Suresnes 92151, France
    Eur Urol 41:608-13; discussion 613. 2002
    ....
  2. ncbi [Study of survival after cystectomy for bladder cancer. Report of 504 cases]
    T Lebret
    Service d Urologie, Hopital Foch, Suresnes, France
    Prog Urol 10:553-60. 2000
    ....
  3. ncbi After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?
    Thierry Lebret
    Department of Urology, Hopital Foch, 40 rue Worth, 92151 Suresnes, France
    Eur Urol 42:344-9; discussion 349. 2002
    ..The aim of this study was to evaluate the outcome of patients who underwent neobladder replacement despite bladder cancer metastasis to the regional lymph nodes...
  4. ncbi [Treatment of bladder tumors]
    Thierry Lebret
    Service d urologie Hôpital Foch 92151 Suresnes
    Rev Prat 52:36-42. 2002
    ..To prevent recurrence, both (superficial or infiltrating) tumour require very strict follow-up for many years...
  5. ncbi A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction
    Y Neuzillet
    Department of Urology, Hopital Foch, Suresnes, France
    Andrology 1:223-8. 2013
    ....
  6. ncbi [Are therapeutics decisions homogeneous in multidisciplinary onco-urology staff meeting? Comparison of therapeutic options taken in four departments from Paris]
    F Audenet
    Service d Urologie, Universite Paris Descartes, Hopital Europeen Georges Pompidou, AP HP, 20, rue Leblanc, 75015 Paris, France
    Prog Urol 22:433-7. 2012
    ..The aim of this study was to compare the therapeutic decision taken in four RCP in Paris Île-de-France academic centres for three identical cases...
  7. ncbi Electrovaporization of the prostate with the Gyrus device
    H Botto
    Department of Urology H pital Foch, Suresnes, France
    J Endourol 15:313-6. 2001
    ..e., 1-year follow-up) should be evaluated. This pilot series permits a comparative study with TURP to assess the benefits for patients and the health care system...
  8. ncbi [Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer]
    M O Timsit
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S365-75. 2008
    ..Early introduction of docetaxel raises the issue of when to start chemotherapy as it may be relevant to initiate this treatment before the onset of hormone independence. GETUG 15 trial will try to answer this question...
  9. ncbi [Is the cytoreductive nephrectomy still necessary in case of metastases?]
    T Lebret
    Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
    Prog Urol 20:S33-7. 2010
    ..Until results of prospective studies, the cytoreductive nephrectomy should be still considered as component of the treatment of metastatic renal cell carcinoma...
  10. ncbi [The impact of partial nephrectomy on morbidity and on long-term oncological outcomes]
    Y Rouach
    Service d Urologie, Hopital Necker, Universite Rene Descartes, 69, rue Saint Martin, 75004 Paris, France
    Prog Urol 19:481-6. 2009
    ..To evaluate the impact of imperative indication on the rate of complications and long term carcinological results after partial nephrectomy (PN)...
  11. ncbi [Medical treatment of metastatic germ cell cancers]
    M O Timsit
    Service d Urologie, Université Paris Descartes Hôpital Necker, France
    Prog Urol 18:S376-81. 2008
    ..Precise predictive factors of recurrence are needed to better define indications of first and other lines of treatment in specific situations such as non-resected residual seminoma...
  12. ncbi [Angiogenesis: the renal cancer model]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S309-14. 2008
    ..VEGF binds to his receptors present on endothelial cells to promote tumoral angiogenesis. Targeted therapy inhibit tumoral blood vessels growth and involves probably others complex mechanisms...
  13. ncbi [Rare locations of metastases from germ cell cancers]
    Y Neuzillet
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S388-91. 2008
    ..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary prostate carcinoma lesions...
  14. ncbi [Rare locations of metastases from penile cancer]
    Y Neuzillet
    Service d Urologie, Hopital Foch, Faculté de médecine Paris Ouest UVSQ, France
    Prog Urol 18:S396-8. 2008
    ..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary urothelial carcinoma lesions...
  15. ncbi [Oncogeriatric evaluation for elderly patients suffering from metastatic urologic malignancies]
    Y Neuzillet
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S415-25. 2008
    ..The scales of assessment of competitive morbidity and measurement of the level of activity now available provide useful prognostic information to help the urologist to make the best decision concerning the therapeutic approach...
  16. ncbi [Rare locations of metastases from renal carcinoma]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S320-6. 2008
    ..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary renal carcinoma lesions...
  17. ncbi [Management of the side effects of androgenic deprivation]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S338-42. 2008
    ..They can and must be prevented by advice on physical activity and nutrition...
  18. doi [Functional evaluation of the orthotopic Z-shaped ileal detubulated neobladder with a minimal 5-year follow-up]
    M Demesmaeker
    Service d Urologie, Hopital Foch, Suresnes, France
    Prog Urol 20:49-55. 2010
    ..Study and evaluate the orthotopic Z-shaped neobladder in the long term and life quality of patients bearing this type of replacement...
  19. doi [Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculté de Médecine de Paris Ile de France Ouest, UVSQ, 40, rue Worth, 92150 Suresnes, France
    Prog Urol 21:301-7. 2011
    ....
  20. ncbi [Metastatic diffusion, angiogenesis and metastasogenesis]
    A Mejean
    Service d Urologie, Hopital Necker, Universite Paris Descartes, 149 rue de Sevres, Paris, France
    Prog Urol 20:S5-10. 2010
    ..At the opposite, the concept of a metastatic gene expression pattern which is (or is not) expressed in the primary tumor is in opposition with the classical clonal selection hypothesis...
  21. ncbi [Role of hormonotherapy in the treatment of metastatic prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S332-7. 2008
    ....
  22. ncbi Evaluation of tension-free vaginal tape procedure. Its safety and efficacy in the treatment of female stress urinary incontinence during the learning phase
    T Lebret
    Department of Urology, Hospital Foch, Suresnes, France
    Eur Urol 40:543-7. 2001
    ..Nevertheless, our results confirm that TVT appears to be an efficient procedure: 97% of patients were cured or improved when UCP >25 cm H2O, 85% when UCP <25 cm H2O and 87% when a PR was associated...
  23. ncbi [Rare locations of metastases from prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ Hôpital Necker, France
    Prog Urol 18:S357-64. 2008
    ..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary prostate carcinoma lesions...
  24. ncbi [Management of toxicities due to anti-angiogenic treatment of metastatic renal carcinoma]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S315-9. 2008
    ..The consequences on the physiological microvasculature could be at the origin of the adverse effects. It seems important for the clinician to know the physiopathology and the management of these toxicities...
  25. ncbi [Metastastic urothelial carcinoma: is there a role for surgery?]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S285-8. 2008
    ..Metastasis resection can also be proposed in association with chemotherapy in case of complete response. In case of non responsive metastasis, metastasectomy can also de discussed in order to improve quality of life...
  26. doi [Healing and targeted therapies: Management in perioperative period?]
    G Pignot
    Service d Urologie, Hopital Cochin, Universite Rene Descartes, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Prog Urol 21:166-72. 2011
    ....
  27. ncbi [How to manage bone metastasis in prostate cancer. A case report]
    T Lebret
    Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
    Prog Urol 20:S72-6. 2010
    ..Metastasis surgery has functional results and should be performed before major neurologic symptoms occur. Metabolic radiotherapy is an option for multifocal bone metastases...
  28. ncbi [PET-FDG in metastases from urological malignancies]
    P Labarthe
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S208-12. 2008
    ..Nevertheless, interpretation is often made difficult by tracer urinary excretion. New radio tracers are being tested and will probably lead to new indications. Research on androgen receptors and molecular imaging is ongoing...
  29. ncbi [Supportive care for urological metastatic patients]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S410-4. 2008
    ..It also includes financial allowances. In France, supportive care centers are being set up in most hospital to facilitate the coordination of all the multidisciplinary teams...
  30. doi [Indications for ablative treatment in kidney cancer in the elderly]
    L Froger
    Service d Urologie, CHU Saint Louis, Paris, France
    Prog Urol 22:1004-9. 2012
    ..Approximately, 30% of kidney cancers are diagnosed in patients over 75 years, mostly by fortuitously. This review had identified the indications of ablative treatment among others options for kidney cancer in these elderly patients...
  31. ncbi [The journey of a molecule, from trials to approval: the specific area of oncology]
    T Lebret
    Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
    Prog Urol 20:S1-4. 2010
    ..Here we discuss the motivations of the pharmaceutical industry in oncology so that the medico-surgical specialist of the cancers of the genito-urinary tract can best understand the situation...
  32. ncbi [Physiopathology, diagnosis and management of bone metastases from prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S349-56. 2008
    ..Endothelin inhibitors belong to a new exciting concept to treat these bone metastases, data are needed in order to use them routinely...
  33. ncbi [Bladder tumour treatment: the real BCG definitive contra-indications]
    Y Neuzillet
    Service d Urologie, Hopital Foch, rue Worth, Suresnes, France
    Prog Urol 20:S41-5. 2010
    ..These specific circumstances require more studies and data if they are no longer to be considered as a contra-indication...
  34. ncbi [How to read and assess oncological scientific research articles in English?]
    Y Neuzillet
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S430-4. 2008
    ..Results and statistical analysis should be evaluated by the reviewer, keeping in mind that the weight of evidence is not correlated to the "p" value...
  35. doi [Bone prevention in prostate cancer]
    T Bessede
    Service d Urologie, Hopital Bicetre, 78, rue du General Leclerc, 94275 Le Kremlin Bicetre cedex, France
    Prog Urol 21:S58-62. 2011
    ..These agents may have a preventive effect on metastasis occurrence, but it has to be confirmed. An intra-venous biphosphonate or a sub-cutaneous RANK-inhibitor administration prevent from bone metastasis-related events...
  36. ncbi [Targeted therapies]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S228-33. 2008
    ..An important number of drugs is still approved. However the metastatic disease is not yet curable. A better understanding will lead to develop others new targeted molecules or more efficient combination therapy...
  37. ncbi [Metastases from squamous cell carcinoma of the penis]
    F Iborra
    CHU de Montpellier, Hopital Lapeyronie, Service d Urologie, France
    Prog Urol 18:S392-5. 2008
    ..Metastasis diagnosis is carried out with TDM and MRI but markers can sometimes be helpful (ie SSCAg). There is no referent chemotherapy, a trial has been started (CAVER)...
  38. doi [Treatment of infiltrating nonmetastatic bladder cancers in elderly patients]
    H Quintens
    Service d Urologie, Institut A Tzanck, Avenue du Docteur Dodat, 06700 Nice, France
    Prog Urol 19:S135-41. 2009
    ..Thus, with multidisciplinary consensus and adapted management, elderly patients with significant comorbidities should not be automatically excluded from access to effective treatment of these cancers...
  39. ncbi [Management of metastatic androgeno-independent prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S343-8. 2008
    ..It is also possible to use estrogen or, in a few cases, to propose chemotherapy...
  40. ncbi [The natural history of metastatic prostate cancer]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S327-31. 2008
    ..At each step of the metastatic cascade, it is possible to imagine a specific targeted therapy for this disease which is today non curable...
  41. ncbi [The physiopathology of metastases: from primary to secondary]
    T Lebret
    Service d Urologie, Hopital Foch, Faculté de médecine Paris Ouest UVSQ
    Prog Urol 18:S147-55. 2008
    ..At each step, there are defence and regulation mechanisms which, when they fail, lead to metastatic dissemination...
  42. ncbi [The metastatic cascade: angiogenesis and new concepts]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S156-66. 2008
    ..The capacity to colonize one organ and not another could be explained by the "seed and soil" theory which postulates that tumor cells (the seed) will only grow in an...
  43. ncbi [Targets, pathways and molecules]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S173-7. 2008
    ..Thus it is possible to define targets which can be receptors, molecules or proteins and consequently develop active drugs for targeted therapy...
  44. ncbi [Role and technical aspects of surgery for spinal metastases from urological malignancies]
    S Gaillard
    Service de Neurochirurgie, Hopital Foch, Suresnes, France
    Prog Urol 18:S239-45. 2008
    ..The choices of therapeutic approach are quite large ranging from percutaneous cimentoplasty to vertebral replacement. It is essential that the initial treatment of metastasis be discussed before neurologic signs appear...
  45. ncbi [Metastases from urethelial carcinoma: role of chemotherapy]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S261-76. 2008
    ..After failure of first line therapy no consensual drugs exist in the second line, ongoing trials and new agents should increase options in the future...
  46. ncbi [Metastases from urothelial carcinoma : future and prospects]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S277-84. 2008
    ..Furthermore, the development of the concept of individualized treatment through identification of molecular prognostic factors and the application of targeted therapy have gained huge interest...
  47. ncbi [Rare locations of metastases from urothelial carcinoma]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ, France
    Prog Urol 18:S289-97. 2008
    ..Nevertheless many other areas have also been described. Using Pubmed and Cochrane the most exhaustive research possible has been carried out to list these secondary urothelial carcinoma lesions...
  48. ncbi [Prise en charge of metastatic renal carcinoma]
    A Mejean
    Service d Urologie, Universite Paris Descartes, France
    Prog Urol 18:S298-308. 2008
    ..Because of a poor prognosis trials testing combination of therapies are required to benefit patients. At least nephrectomy is necessary looking forward prospective studies to estimate its real impact...
  49. ncbi [Bladder replacement and cancer of the bladder]
    T Lebret
    Service d Urologie, Hopital Foch, Suresnes, France
    Prog Urol 19:872-80. 2009
    ..The correct functioning of the neo-bladder should be verified regularly in order to ensure that the bladder is emptied properly. Continence returns through auto-exercise...
  50. doi [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results]
    Y Neuzillet
    Service d Urologie, Hopital Foch, Université de Versailles Saint Quentin en Yvelines UVSQ, 92150 Suresnes, France Electronic address
    Prog Urol 23:S34-43. 2013
    ..This article aims to describe the mechanisms of action of these new hormonal treatments and their major clinical outcomes and development programs...
  51. doi Effects of nucleotides adenosine monophosphate and adenosine triphosphate in combination with L-arginine on male rabbit corpus cavernosum tissue
    V Hupertan
    Department of Urology, Hopital Bichat, Paris, France
    Int J Androl 35:860-6. 2012
    ..The present data indicate that a 'NO donor' combined with an 'adenosine donor' could be an effective therapeutic approach...
  52. doi [Patient information and professional responsibility: reversal of jurisprudence of the Court of cassation]
    M Rouanne
    Service d Urologie, Faculte de Medecine Paris Ile de France Ouest, Hopital Foch, UVSQ, 40, rue Worth, 92150 Suresnes, France
    Prog Urol 22:67-9. 2012
    ..In accordance with this decision, a new jurisprudence in medical responsibility is born...
  53. ncbi [Urolithiasis, CT and lithotripsy guidelines]
    A Scherrer
    Service de Radiologie, Hopital Foch, Suresnes, France
    J Radiol 81:1039-51. 2000
    ..practitioner, the radiologist and the urologist should answer three questions that will be reviewed in this paper: Is the acute flank pain caused by urolithiasis? Will calculus be spontaneously discharged? Is lithotripsy indicated?..
  54. ncbi [Metastases from urologic malignancies: history, definitions and strategies]
    T Lebret
    Service d Urologie, Hopital Foch, Faculte de Medecine Paris Ile de France Ouest, UVSQ
    Prog Urol 18:S143-6. 2008
    ..Today, even if all is not totally understood, physicians know that metastasis is a decisive event in the carcinoma story...
  55. ncbi TSC2/PKD1 contiguous gene syndrome in an adult
    T Culty
    Department of Urology, CHU Pitie Salpetriere, Paris, France
    Minerva Urol Nefrol 58:351-4. 2006
    ..The clinical and pathological presentation is consistent with the diagnosis of TSC2/PKD1 contiguous gene syndrome, caused by the simultaneous loss of TSC2 and PKD1, the two major genes for tuberous sclerosis complex and ADPKD...
  56. ncbi Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
    Laurent Guy
    Department of Urology, CHU Clermont Ferrand, France
    Eur Urol 50:516-20; discussion 520. 2006
    ..Vesical biopsies often are performed to assess the efficacy of treatment. The aim of our study was to evaluate the usefulness of these biopsies...
  57. ncbi HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours
    Thierry Lebret
    Department of Urology and Pathology, Hopital Foch, Suresnes, France
    Eur Urol 51:161-6; discussion 166-7. 2007
    ..This study attempted to evaluate if heat shock proteins (HSPs) could be useful predictive markers in BCG responses...
  58. doi [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?]
    Thierry Lebret
    Service d Urologie, Hopital Foch, 40 rue Worth, Suresnes, France
    Prog Urol 18:S111-4. 2008
    ..In both cases (early, before BCG treatment, or after BCG treatment failure), this excision therapy should be practiced rapidly because the risk of progression is high and cystectomy tolerates no delay when indicated...
  59. ncbi [Upper urinary tract tumor: conservative treatment of localized forms]
    Jacques Irani
    Service d Urologie, CHU La Miletrie, 86000 Poitiers
    Prog Urol 13:555-9. 2003
  60. ncbi Prostatic capsule- and seminal-sparing cystectomy for bladder carcinoma: initial results for selected patients
    Henry Botto
    Department of Urology, Hopital Foch, Suresnes, France
    BJU Int 94:1021-5. 2004
    ....
  61. ncbi [Urothelial tumors]
    Jacques Irani
    Prog Urol 14:957, 959-96. 2004
  62. ncbi Peyronie's disease
    John Pryor
    Institute of Urology, London University, London, UK
    J Sex Med 1:110-5. 2004
    ..Peyronie's disease is a sexual medicine condition that may adversely affect male sexual function...
  63. ncbi [Superficial grade G2 tumors of the bladder: recurrence, progression, prognosis]
    Philippe Sebe
    Service d Urologie, Hopital Foch, 40, rue Worth, BP 36, 92150 Suresnes
    Prog Urol 13:608-12. 2003
    ....
  64. ncbi [Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]
    Jacques Irani
    Comite Tumeurs Urothéliales du CCAFU
    Prog Urol 15:581-6. 2005
    ....
  65. ncbi [Urothelial tumors]
    Jacques Irani
    Prog Urol 17:1065-98. 2007
  66. ncbi Treatment of postprostatectomy stress urinary incontinence using a minimally invasive adjustable continence balloon device, ProACT: results of a preliminary, multicenter, pilot study
    Thierry Lebret
    Department of Urology, Hopital Foch, Suresnes, France
    Urology 71:256-60. 2008
    ..To evaluate the safety and efficacy of a new minimally invasive device, Adjustable Continence Therapy (ProACT) for patients with postprostatectomy stress urinary incontinence (SUI)...
  67. ncbi [Infiltrating bladder tumours]
    Thierry Lebret
    Service d Urologie, Hopital Foch, 92150 Suresnes
    Rev Prat 57:630-40. 2007
    ..In case of recurrence, therapeutic options should be debated in multidisciplinary team meetings; chemotherapy with cisplatin or/and gemcitabine remains the main therapeutic weapon...